Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs antibody agreement

Japan-based pharmaceutical firm Astellas is to enter a license agreement with biotechnology firm Evec for its antibody programme to fight infectious diseases

Japan-based pharmaceutical firm Astellas is to enter a license agreement with biotechnology firm Evec for its antibody programme to fight infectious diseases.

The deal will see Astellas gain worldwide rights to develop, manufacture and commercialise the related antibodies, with the programme still in a pre-clinical phase.

Evec will receive an upfront payment of 0.6bn yen, with potential milestone payments based on development and sales success of up to 13bn yen.

The company specialises in the development of a number of human monoclonal antibodies across several therapeutic areas, including cancer, inflammatory diseases and infectious diseases.

6th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics